XML 52 R42.htm IDEA: XBRL DOCUMENT v3.25.3
Industry Segment Information (Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 28, 2025
Sep. 29, 2024
Sep. 28, 2025
Sep. 29, 2024
Segment Reporting Information [Line Items]        
Segment revenue $ 698,949 $ 684,049 $ 2,083,995 $ 2,025,654
Total amortization expense related to finite-lived intangible assets 84,100 89,600 252,100 271,500
Operating income (loss) from continuing operations 81,896 98,151 244,886 227,991
Interest and other expense (income), net 26,211 (2,206) 68,169 6,423
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 55,685 100,357 176,717 221,568
Product [Member]        
Segment Reporting Information [Line Items]        
Segment revenue 573,225 579,997 1,742,983 1,717,927
Service [Member]        
Segment Reporting Information [Line Items]        
Segment revenue 125,724 104,052 341,012 307,727
Diagnostics [Member]        
Segment Reporting Information [Line Items]        
Segment revenue 356,127 345,249 1,034,880 1,001,815
Segment operating income 89,376 93,848 252,813 262,801
Life Sciences [Member]        
Segment Reporting Information [Line Items]        
Segment revenue 342,822 338,800 1,049,115 1,023,839
Segment operating income 101,048 110,565 322,228 329,083
Reportable Segment Revenue [Member]        
Segment Reporting Information [Line Items]        
Segment revenue 698,949 684,049 2,083,995 2,025,654
Reportable Segment Revenue [Member] | Diagnostics [Member]        
Segment Reporting Information [Line Items]        
Segment revenue 356,127 345,249 1,034,880 1,001,815
Reportable Segment Revenue [Member] | Life Sciences [Member]        
Segment Reporting Information [Line Items]        
Segment revenue 342,822 338,800 1,049,115 1,023,839
Segment Operating Income [Member]        
Segment Reporting Information [Line Items]        
Segment operating income 190,424 204,413 575,041 591,884
Segment Operating Income [Member] | Diagnostics [Member]        
Segment Reporting Information [Line Items]        
Segment Cost of Revenue 158,900 144,653 450,130 421,836
Segment Selling, general and administrative expenses 84,719 84,116 258,736 249,996
Segment research and development expenses 23,132 22,632 73,201 67,182
Segment Operating Income [Member] | Life Sciences [Member]        
Segment Reporting Information [Line Items]        
Segment Cost of Revenue 129,976 117,546 384,325 361,534
Segment Selling, general and administrative expenses 84,190 84,944 258,271 255,048
Segment research and development expenses 27,608 25,745 84,291 78,174
Reconciling Item (to Reconcile Segment Operating Income to Income from Continuing Operations before Income Taxes) [Member]        
Segment Reporting Information [Line Items]        
Corporate Expenses (8,008) (10,915) (30,912) (33,725)
Total amortization expense related to finite-lived intangible assets (84,074) (89,642) (252,063) (271,500)
Purchase accounting adjustments (348) (103) (2,349) (7,348)
Acquisition and divestiture-related costs (284) (4,874) (2,950) (22,115)
Transformation costs (5,103) 0 (6,226) 0
Significant litigation matters and settlements (785) (810) (12,495) (7,086)
Restructuring and other, net $ (9,926) $ 82 (24,368) (22,119)
Significant environmental matters     $ 1,208 $ 0